Ryo Oka1, Takanobu Utsumi2, Takumi Endo1, Masashi Yano1, Shuichi Kamijima1, Naoto Kamiya1, Kohji Shirai3, Hiroyoshi Suzuki1. 1. Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan. 2. Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan. takanobu.utsumi@med.toho-u.ac.jp. 3. Seijinkai-Mihama Hospital, 1-1-5 Utase, Mihama-ku, Chiba, Chiba, 261-0013, Japan.
Abstract
BACKGROUND: To explore arterial stiffness during the administration of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa), a new indicator, the cardio-ankle vascular index (CAVI), and serum lipid profile changes were monitored. METHODS: A prospective study assessed the changes in arterial stiffness using the CAVI and clinical laboratory variables among 58 men with prostate cancer treated with ADT for 6 months. Furthermore, patients who had a high risk of developing arterial stiffness after ADT were investigated. RESULTS: The whole cohort had no significant increase in arterial stiffness within 6 months after ADT, but 55.2 % of patients had an increased CAVI. Serum levels of total cholesterol, high-density-lipoprotein cholesterol (HDL-C), and low-density-lipoprotein cholesterol (LDL-C) increased significantly at 1 month after the start of ADT and maintained high values thereafter. At baseline, HDL-C was lower and LDL-C and LDL-C/HDL-C were higher in the group with than without an increased CAVI after 6 months of ADT administration. CONCLUSIONS: Although the whole cohort did not show a significant change in arterial stiffness with ADT, some patients showed an increased arterial stiffness monitored with the CAVI. The balance between LDL-C and HDL-C, or LDL-C/HDL-C, might have an impact on the development of arterial stiffness after ADT administration. Thus, clinicians might be able to monitor PCa patients who have a high risk of development of arterial stiffness after ADT administration by referring to LDL-C/HDL-C levels.
BACKGROUND: To explore arterial stiffness during the administration of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa), a new indicator, the cardio-ankle vascular index (CAVI), and serum lipid profile changes were monitored. METHODS: A prospective study assessed the changes in arterial stiffness using the CAVI and clinical laboratory variables among 58 men with prostate cancer treated with ADT for 6 months. Furthermore, patients who had a high risk of developing arterial stiffness after ADT were investigated. RESULTS: The whole cohort had no significant increase in arterial stiffness within 6 months after ADT, but 55.2 % of patients had an increased CAVI. Serum levels of total cholesterol, high-density-lipoprotein cholesterol (HDL-C), and low-density-lipoprotein cholesterol (LDL-C) increased significantly at 1 month after the start of ADT and maintained high values thereafter. At baseline, HDL-C was lower and LDL-C and LDL-C/HDL-C were higher in the group with than without an increased CAVI after 6 months of ADT administration. CONCLUSIONS: Although the whole cohort did not show a significant change in arterial stiffness with ADT, some patients showed an increased arterial stiffness monitored with the CAVI. The balance between LDL-C and HDL-C, or LDL-C/HDL-C, might have an impact on the development of arterial stiffness after ADT administration. Thus, clinicians might be able to monitor PCa patients who have a high risk of development of arterial stiffness after ADT administration by referring to LDL-C/HDL-C levels.
Authors: Juan Morote; Antonio Gómez-Caamaño; José L Alvarez-Ossorio; Daniel Pesqueira; Angel Tabernero; Francisco Gómez Veiga; José A Lorente; Mariano Porras; Juan J Lobato; María J Ribal; Jacques Planas Journal: J Urol Date: 2014-12-23 Impact factor: 7.450
Authors: J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Richard D Jones; Kate M English; Peter J Pugh; Alyn H Morice; T Hugh Jones; Kevin S Channer Journal: J Cardiovasc Pharmacol Date: 2002-06 Impact factor: 3.105
Authors: C Alicia Traughber; Emmanuel Opoku; Gregory Brubaker; Jennifer Major; Hanxu Lu; Shuhui Wang Lorkowski; Chase Neumann; Aimalie Hardaway; Yoon-Mi Chung; Kailash Gulshan; Nima Sharifi; J Mark Brown; Jonathan D Smith Journal: J Biol Chem Date: 2020-05-01 Impact factor: 5.157
Authors: Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub Journal: Circulation Date: 2019-03-26 Impact factor: 29.690
Authors: Edyta Wolny-Rokicka; Andrzej Tukiendorf; Jerzy Wydmański; Małgorzata Ostrowska; Agnieszka Zembroń-Łacny Journal: Am J Mens Health Date: 2019 Sep-Oct
Authors: Chi-Fai Ng; Peter K F Chiu; Chi-Hang Yee; Becky S Y Lau; Steven C H Leung; Jeremy Y C Teoh Journal: Sci Rep Date: 2020-10-22 Impact factor: 4.379